Expanded ROS Generation and Hypoxia Reversal: Excipient‐free Self‐assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy

Abstract The efficacy of photodynamic therapy (PDT)‐related cancer therapies is significantly restricted by two irreconcilable obstacles, i.e., low reactive oxygen species (ROS) generation capability and hypoxia which constrains the immune response. Herein, this work develops a self‐assembled clinical photosensitizer indocyanine green (ICG) and the HSP90 inhibitor 17‐dimethylaminoethylamino‐17‐demethoxygeldanamycin (17‐DMAG) nanoparticles (ISDN) without any excipient. This work discovers that the hydrophobic interaction forces between ICG and 17‐DMAG promote the photostability of ICG and its intersystem crossing (ISC) process, thereby improving the ROS quantum yield from 0.112 to 0.46. Augmented ROS generation enhances PDT efficacy and further enhances immunogenic cell death (ICD) effects. 17‐DMAG inhibits the HSP90/hypoxia‐inducible factor 1α (HIF‐1α) axis to dramatically reverse the immunosuppressive tumor microenvironment caused by PDT‐aggravated hypoxia. In a mouse model of pancreatic cancer, ISDN markedly improve cytotoxic T lymphocyte infiltration and MHC I and MHC II activation, demonstrating the superior ICD effects in situ tumor and the powerful systematic antitumor immunity generation, eventually achieving vigorous antitumor and recurrence resistance. This study proposes an unsophisticated and versatile strategy to significantly improve PDT efficacy for enhancing systemic antitumor immunity and potentially extending it to multiple cancers.